What's the Latest Buzz in Biologics?

Bone grafts are widely available, but finding ones backed by solid level-1 evidence is a challenge. It’s refreshing to see a company prioritizing research over revenue, especially as it now focuses on the foot and ankle market segment. 

MagnetOs

Kuros Biosciences has successfully completed a notable level-1 study on posterior lateral fusion, setting the stage for its expansion into the extremity market. Kuros' core technology, the MagnetOs bone graft platform, uses nano architecture to interact with macrophages to harness the human immune system and stimulate bone healing. The spine community has responded enthusiastically, with MagnetOs achieving an impressive revenue of $85 million in 2024. 

Track record of success

As it steps into 2025, Kuros has assembled a dedicated internal extremities team led by Jantzen Cole, former vice president of marketing at Artelon. While the team faces the challenge of increasing brand awareness and replicating its success in the spine market within the foot and ankle segment, its first time appearance at ACFAS conference created a significant impact.